iThermonitor | Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies
post-template-default,single,single-post,postid-1,single-format-standard,qode-news-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-theme-ver-16.7,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.2,vc_responsive

Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies

Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies

We conducted this study in conjunction with the Dana Farber Cancer Institute, and Mass General Hospital sponsored the study. It was initiated in March of 2015 and the Final Report was published in June of 2017. The following are excerpts from the final report:

Fever is often the first sign of an underlying inflammatory process and, in children, can be one of the earliest indicators that alerts caregivers to seek medical attention. In children who have undergone chemotherapy or surgery, episodic monitoring of body temperature by caregivers has traditionally been the only option for early detection of fever. This adds significant burden to the already demanding process of taking care of a sick child. In this study, we evaluated the usability and feasibility of iThermonitor™, an innovative device that continuously monitors body temperature and automatically transmits the data wirelessly to mobile devices , so that caregivers can remotely view or track fever patterns. It also has the ability to detect and alert caregivers about out-of-range temperatures.

The primary outcome was the use feasibility of the device,defined as device usage for 80% of time in the study by at least 80%of the participants. Secondary outcomes included usability,  acceptability ,satisfaction and engagement with the device,assessed through the endline surveys.The Generalized Anxiety Disorder-7(GAD-7) questionnaire was used to assess caregiver anxiety immediately before and after the study period.

71% of the participants were cancer patients undergoing chemotherapy while the remaining were non-cancer post-surgical patients. All 19 caregivers viewed temperature data on the study provided iPad tablet at least once per day and more than a third did so 6 or more times per day, which meets feasibility criteria set for the device. Caregivers of children undergoing chemotherapy were twice as likely to report viewing temperature data six or more times per day as compared to caregivers of children who had undergone surgery.   

A vast majority of caregivers were satisfied with the usability of the iThermonitor device and reported feeling more confident about monitoring temperature using the device. 95% of the caregivers were assessed to have no or mild anxiety at the end of the study period, compared to 79% at the beginning.  

Click here for the official clinical trial webpage.

No Comments

Post A Comment